Chromogranin As a Biochemical Marker of Neuroendocrine Tumors
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Comparative study of plasma chromogranin A levels was carried out in 227 patients with neuroendocrine tumors of various locations and 66 normal subjects, men and women, by standard ELISA. In patients with tumors of all locations (pancreas, stomach, small and large intestine, and lungs), the glycoprotein levels were significantly (p<0.000001) higher than in controls. The patients demonstrated high variability of chromogranin A levels; the maximum concentrations were detected in patients with neuroendocrine tumors of the stomach and lung. The highest median values of chromogranin A were found in patients with tumors of the small intestine, large intestine, and pancreas. A relationship between secretion of chromogranin A and dissemination and activity of the neuroendocrine tumor was detected, which was the maximum in patients with metastases in the liver and carcinoid syndrome. High diagnostic sensitivity of chromogranin A was shown: 85.8% for the total group of patients; specificity was 98.5%. These data confirmed high efficiency of chromogranin A as the marker of neuroendocrine tumors. Detection of this marker promotes more accurate diagnosis and evaluation of dissemination of the neuroendocrine tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In accordance with previous studies, we found that normal CgA does not exclude NET, since 6 of 25 diagnosed patients did not have elevated plasma CgA [5,16].”
From Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors (2020) · cites this paper as [16]
In the citing paper
“All patients with metastatic disease had elevated CgA concentrations whereas half of patients with localized disease had elevated CgA, strengthening the idea that CgA is more sensitive in disseminated disease compared to localized disease [16,17,18,30,31].”
From Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors (2020) · cites this paper as [16]
Citations
Cites
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
O’Toole, D., Grossman, A., Gross, D., Delle Fave, G., Barkmanova, J., O’Connor, J., Pape, U.-F., & Plöckinger, U. (2009) · Neuroendocrinology · doi:10.1159/000225948 · Cited by 268
Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana, D., Nori, F., Piscitelli, L., Morselli-Labate, A. M., Pezzilli, R., Corinaldesi, R., & Tomassetti, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1535 · Cited by 248
Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours
Öberg, K. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0280 · Cited by 112
Feldman, S. A., & Eiden, L. E. (2003) · Endocrine Pathology · doi:10.1385/ep:14:1:3 · Cited by 95
Nikou, G. C., Marinou, K., Thomakos, P., Papageorgiou, D., Sanzanidis, V., Nikolaou, P., Kosmidis, C., Moulakakis, A., & Mallas, E. (2008) · Pancreatology · doi:10.1159/000152000 · Cited by 84
Singh, S., & Law, C. (2012) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.12.15 · Cited by 59
Circulating markers for endocrine tumours of the gastroenteropancreatic tract
Ardill, J. E. S. (2008) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2008.008039 · Cited by 54
Chromogranins: Current Concepts
Aunis, D., & Metz‐Boutigue, M. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46837-9_2 · Cited by 25
Research works printed but not linked: 1
- N. V. Lyubimova and N. E. Kushlinskii, Vopr. Biol. Med. Farm. Khim., 12, No. 1, 48-58 (2014).
Cited by
Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors
Giacinto, P. D., Rota, F., Rizzà, L., Campana, D., Isidori, A. M., Lania, A. G., Lenzi, A., Zuppi, P., & Baldelli, R. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8126087 · Cited by 74
“In several clinical trials recruiting patients suffering from thoracic neuroendocrine tumors (tNETs), the tumor grade, treatment method, and Cg A status show significant correlation with survival [93].”
The paracrine induction of prostate cancer progression by caveolin-1
Lin, C., Yun, E.-J., Lo, U., Tai, Y.-L., Deng, S., Hernández, E., Dang, A., Chen, Y., Saha, D., Mu, P., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2066-3 · Cited by 73
Takeuchi, T., Furuta, T., Fujiwara, Y., Sugimoto, M., Kasugai, K., Kusano, M., Okada, H., Suzuki, T., Higuchi, T., Kagami, T., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15641 · Cited by 70
Tirosh, A., Papadakis, G. Z., Millo, C., Sadowski, S. M., Herscovitch, P., Pacák, K., Marx, S. J., Yang, L., Nockel, P. J., Shell, J., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-1079 · Cited by 53
Al-Risi, E. S., Al-Essry, F. S., & Mula-Abed, W.-A. S. (2017) · Oman Medical Journal · doi:10.5001/omj.2017.71 · Cited by 41
Metadata
- Authors
- Lyubimova, N. V., Churikova, T. K., & Kushlinskii, N. E.
- Affiliations
- Russian Cancer Research Center NN Blokhin (RU)
- Corresponding author
- Lyubimova, N. V.
- ORCID
- Lyubimova, N. V.
- Venue
- Bulletin of Experimental Biology and Medicine
- Published
- 2016-03
- Volume
- 160
- Issue
- 5
- Pages
- 702-704
- ISSN
- 0007-4888 (ISSN-L)
- 1573-8221
- OpenAlex
- W2316555918
- Cited by
- 20
- References
- 9
- Citations by year
- 2026: 1 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 2
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Bulletin of Experimental Biology and Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- chromogranin A, neuroendocrine tumors, tumor markers, sensitivity and specificity, carcinoid syndrome, liver metastasis, metastasis, pancreatic neuroendocrine tumors, gastric neuroendocrine tumor, small bowel neuroendocrine tumors, lung neuroendocrine tumors
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Sensitivity and Specificity, Biomarkers, Tumor, Neuroendocrine Tumors, Chromogranin A, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chromogranin As a Biochemical Marker of Neuroendocrine Tumors. https://app.cochat.ai/papers/10.1007/s10517-016-3254-0
- The paper
- Lyubimova, N. V., Churikova, T. K., & Kushlinskii, N. E. (2016). Chromogranin As a Biochemical Marker of Neuroendocrine Tumors. Bulletin of Experimental Biology and Medicine. https://doi.org/10.1007/s10517-016-3254-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.